Phase 2 trial results for the investigational vaccine were presented at IDWeek 2026 in Washington, DC, as the phase 3 program is currently underway.
Feature|Articles|November 3, 2026
The Uncounted Threat: Antibiotic-Resistant Pneumonia
Author(s)Brian Nowosielski
Matthew Crawford, PhD, of the University of Virginia, and Mario Danek of Qnovia explain what pharmacists can do now and what may come next.
Advertisement
Advertisement
When a patient dies of drug-resistant pneumonia, the death certificate may never say so. Patients who die of resistant hospital-acquired pneumonia are usually in the ICU or long-term care for other conditions, and the underlying illness is what tends to get recorded, according to Mario Danek, founder and CEO of Qnovia.
Related to this article
To guide public health and vaccination strategies, researchers assessed a variety of factors regarding community-acquired pneumonia and its causes.
Approval was given to GSK, making its product the first antisense oligonucleotide established for the treatment of chronic hepatitis B.
The inquiry puts audit practices, including how pharmacies are selected for audit, proportionality, and pharmacy advocacy in focus.
Nolla Derm’s overseeing physician, Zaid Fadul, MD, FS, FAAFP, discusses the revolutionary AI technology that could transform how health care conducts prescribing practices.
As COVID-19 vaccine guidance shifts, new data suggest vaccinated patients face no greater clot or death risk than with other respiratory infections.
Alyssa Eisenberg, PharmD, explores technology’s emerging role in the health care environment and how the pharmacist of the future’s day-to-day tasks might evolve.
In the final portion of our discussion with Kimberly Kue-Tsemo, PharmD, she explores the key developments that could be the most significant push toward reducing pharmacy deserts.
Advertisement
Advertisement